{"id":3394,"date":"2026-01-22T13:13:40","date_gmt":"2026-01-22T11:13:40","guid":{"rendered":"https:\/\/www.elinek.gr\/?p=3394"},"modified":"2026-05-15T13:58:46","modified_gmt":"2026-05-15T10:58:46","slug":"omnibus-viii","status":"publish","type":"post","link":"https:\/\/www.elinek.gr\/en\/omnibus-viii\/","title":{"rendered":"Omnibus VIII Regulation: A New Era of Cosmetic Safety in the EU"},"content":{"rendered":"

Omnibus VIII Regulation: A New Era of Cosmetic Safety in the European Union<\/strong><\/h2>\n

Understanding EU Regulation 2026\/78 and Its Impact on the Cosmetics Industry<\/em><\/p>\n

Introduction<\/strong><\/h2>\n

The European Union has long been at the forefront of consumer safety, particularly in the cosmetics sector. Omnibus VIII Regulation (EU 2026\/78) represents the latest step in this ongoing commitment, introducing significant changes to how cosmetic ingredients are regulated across member states. This regulation, which takes effect on May 1, 2026, marks a critical evolution in the EU’s approach to protecting consumers from potentially harmful substances in cosmetic products.<\/p>\n

What is Omnibus VIII Regulation?<\/strong><\/h2>\n

Omnibus VIII (Regulation EU 2026\/78) is an amendment to the fundamental Cosmetics Regulation (EC) No 1223\/2009. The regulation specifically targets CMR substances\u2014those classified as carcinogenic, mutagenic, or toxic to reproduction\u2014introducing new bans and restrictions on their use in cosmetic products sold throughout the European Union.<\/p>\n

This regulation follows the EU’s established pattern of aligning cosmetics legislation with updated hazard classifications under the CLP Regulation (Classification, Labelling and Packaging).<\/p>\n

<\/span> Implementation Timeline and Application Date<\/strong><\/h2>\n

The regulation’s timeline is notably aggressive compared to previous amendments. Omnibus VIII entered into force in January 2026 and will apply across all EU member states from May 1, 2026. Critically, there are no exceptions or adaptation periods\u2014a departure from typical regulatory transitions that usually allow 12 months or more for market adjustment.<\/p>\n

This strict deadline reflects the EU’s precautionary approach to CMR substances. From May 1, 2026, all non-compliant cosmetic products must be removed from the EU market, regardless of whether they are already on retail shelves or in distribution channels. This creates significant pressure on cosmetics companies to reformulate products and clear existing inventory well before the compliance date.<\/p>\n

Key Amendments and Affected Substances<\/strong><\/h2>\n

Omnibus VIII amends Annexes II through V of the Cosmetics Regulation, which govern prohibited substances and substances permitted only under specific restrictions. The changes affect a range of commonly used cosmetic ingredients, requiring manufacturers to either reformulate products or ensure compliance with new concentration limits.<\/p>\n

Silver Powder<\/strong><\/p>\n

Silver powder now faces regulation based on particle size. When used in toothpaste and mouthwash, it is restricted to a maximum concentration of 0.05%. This size-dependent approach reflects growing scientific understanding of how nanoparticles and microparticles interact differently with human tissue.<\/p>\n

CI 77820 (Color Additive)<\/strong><\/p>\n

Similar to silver powder, CI 77820 is now regulated based on particle size. When particles measure between 100 nanometers and 1 millimeter, the substance is permitted in lip products and eye shadows at concentrations up to 0.2%. This nuanced regulation demonstrates the EU’s sophisticated approach to ingredient safety.<\/p>\n

Newly Banned Substances<\/strong><\/p>\n

Several substances face outright bans under Omnibus VIII:<\/p>\n

Sodium perborate, commonly used as a bleaching agent in cosmetic formulations, is now prohibited due to its CMR classification.<\/p>\n

Multi-walled carbon nanotubes, despite their innovative applications in cosmetics, are banned due to safety concerns related to their structure and potential toxicity.<\/p>\n

Acetone oxime, used in various formulations, also faces prohibition under the new regulation.<\/p>\n

Hexyl Salicylate: A Case Study in Graduated Restrictions<\/strong><\/p>\n

Perhaps the most impactful change in Omnibus VIII concerns hexyl salicylate, a widely used fragrance compound found in countless cosmetic products. The regulation introduces a complex framework of concentration limits that vary by product type and intended user age, reflecting the substance’s CMR Category 2 classification.<\/p>\n

Inhalation and Impurity Concerns<\/strong><\/p>\n

Beyond concentration limits, Omnibus VIII addresses other safety concerns related to hexyl salicylate:<\/p>\n

The substance is not applicable to any sprayable product, including mouth spray, that may lead to exposure through inhalation. This restriction acknowledges the different risk profile associated with inhaled versus topically applied substances.<\/p>\n

If salicylic acid appears as an impurity from the breakdown of hexyl salicylate, it must be maintained at a technically unavoidable trace level. This requirement stems from the fact that salicylic acid itself is not permitted in products for children under three years of age.<\/p>\n

Why Omnibus VIII Matters<\/strong><\/h2>\n

Omnibus VIII represents more than just another regulatory update\u2014it embodies the EU’s evolving philosophy toward cosmetic safety and consumer protection. Several aspects of this regulation deserve particular attention:<\/p>\n

Particle Size as a Safety Factor<\/strong><\/p>\n

The regulation’s focus on particle size, particularly regarding silver powder and CI 77820, illustrates the EU’s sophisticated understanding of how materials behave differently at different scales. Nanoparticles and microparticles can have substantially different toxicological profiles than their bulk counterparts, a reality that Omnibus VIII explicitly acknowledges through its size-dependent restrictions.<\/p>\n

Consolidation of CMR Strategy<\/strong><\/p>\n

Omnibus VIII consolidates the European strategy to eliminate or severely restrict all CMR substances from cosmetic products. This represents a precautionary approach to consumer safety that prioritizes the avoidance of potential long-term health effects, even when immediate risks may appear minimal.<\/p>\n

No Grace Period for Compliance<\/strong><\/p>\n

Unlike other cosmetic amendments that typically provide a year or more to clear non-compliant stock from shelves, CMR bans under Omnibus VIII are stricter. The requirement to remove all non-compliant products by May 1, 2026\u2014regardless of when they entered the market\u2014underscores the seriousness with which the EU views CMR-related risks.<\/strong><\/p>\n

Impact on the Cosmetics Industry<\/strong><\/p>\n

The implementation of Omnibus VIII creates significant operational challenges for cosmetics manufacturers, distributors, and retailers operating in the EU market.<\/p>\n

Reformulation Requirements<\/strong><\/p>\n

Companies must reformulate products containing banned substances or substances exceeding new concentration limits. For hexyl salicylate, which appears in fragrance formulations across countless product lines, this may require extensive reformulation efforts. Perfumers must identify alternative fragrance compounds that can replicate desired scent profiles while maintaining product stability and consumer acceptance.<\/p>\n

Safety Assessment Updates<\/strong><\/p>\n

Many cosmetic products on the EU market that might have recently undergone safety assessments may no longer be compliant with the latest provisions. Companies must review existing safety assessments and potentially commission new evaluations for reformulated products. This creates additional costs and regulatory burden, particularly for smaller manufacturers.<\/p>\n

<\/span> Immediate Action Items<\/strong><\/h2>\n

Cosmetics companies should prioritize several immediate actions to ensure compliance by the May 1, 2026 deadline:<\/p>\n